Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of ...

Fintel reports that on January 21, 2025, RBC Capital downgraded their outlook for CF Industries Holdings (NYSE:CF) from ...

Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Investing.com -- RBC Capital Markets has downgraded both Anglo American (JO: AGLJ) plc and Antofagasta (LON: ANTO) plc to ...

In the last two years, it’s happened for the fifth time. The S&P 500 was up 26% in 2023 and 25% in 2024, for the best ...

RBC Capital Markets raised its recommendation on KB Home (NYSE:KBH) and Lennar (NYSE:LEN), considering the homebuilders' ...

A small change in BBVA’s takeover offer for Banco Sabadell SA announced Thursday seems to be a correction of a previous ...

RBC Capital Markets analyst Maurice Choy identifies relative “safer havens” in the yield-heavy energy infrastructure sector, ...